BiotechTube
BioSapien

BioSapien

San Francisco, United States· Est.
biosapien.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

BioSapien is a private, pre-revenue biotech developing the MediChip™, a 3D-printed, biodegradable implant for localized, sustained drug delivery to solid tumors. The platform aims to mitigate the severe side effects of systemic chemotherapy by targeting the tumor directly, potentially improving outcomes and enabling more patients to undergo curative surgery. The company has secured $3M in total funding, including seed investment from SOSV and Hikma Ventures, and has achieved key regulatory clarity with the FDA's confirmation of a 505(b)(2) approval pathway for its lead program.

Oncology

Technology Platform

MediChip™: a biocompatible, biodegradable, 3D-printed implantable patch for localized, sustained release of drug combinations directly to tumor sites.

Opportunities

The MediChip™ addresses a massive unmet need in oncology by potentially reducing chemotherapy's debilitating systemic side effects, which could drive rapid adoption.
The confirmed 505(b)(2) regulatory pathway offers a faster, lower-cost route to market compared to novel drug development.
The platform's versatility for multiple drugs and solid tumor types creates a broad pipeline opportunity from a single technical foundation.

Risk Factors

The company faces significant technical risk in proving the clinical efficacy and safety of its first-of-a-kind implantable drug delivery system in human trials.
As a pre-revenue startup, it is highly dependent on raising additional capital to fund expensive clinical development.
Commercial success will require overcoming adoption hurdles with surgeons and securing favorable reimbursement from payers.

Competitive Landscape

BioSapien competes in the targeted drug delivery and local therapy space for solid tumors. Direct competitors include companies developing intratumoral injectables, implantable drug-eluting devices, and other localized sustained-release technologies. It also competes indirectly against systemic chemotherapy innovators and other modalities like radiotherapy. Its key differentiator is the combination of biocompatibility, biodegradability, multi-drug capacity, and a direct tissue-adhering form factor.

More companies in Oncology (General) →More companies in United States →